The platform is the mechanism of action and that this particular form of tumor was thought to be one of the most difficult to treat. IMHO, we await final confirmation, but it appears that they have successfully marshaled the immune system past the blood brain barrier and to address this very diverse kind of solid tumor with very many mutations. There are less complex tumors that kill many people and the mechanism would likely be the same.
It is on the order of a Keytruda potentially, except DCVax will likely extend survival, IMHO.
We also have early results, for Direct, and it is based on the same technology, just administered differently.
With the new 21st Century Cures Act reforms working their way through, if DCVax-L is approved, I believe access to the drug for other cancers will be immensely expedited.
Hard to say it’s not a platform. That’s your position and it seems to me you’re incorrect. But everyone has an opinion. I think more people who are looking at this closely, including experts and doctors, likely would say your wrong. But that’s my opinion.
All IMHO.
News 
Market Data 
Discover 
AI
